Feasibility of Combining the Phosphatidylinositol 3-Kinase Inhibitor Copanlisib With Rituximab-Based Immunochemotherapy in Patients With Relapsed Indolent B-cell Lymphoma

Combining oral PI3K inhibitors with immunochemotherapy for indolent B-cell lymphoma has been associated with toxicity. In the Phase III CHRONOS-4 safety run-in, 21 patients received intravenous copanlisib plus rituximab-based immunochemotherapy. There were no dose-limiting toxicities, and preliminar...

Descripción completa

Detalles Bibliográficos
Autores principales: Matasar, Matthew J., Dreyling, Martin, Leppä, Sirpa, Santoro, Armando, Pedersen, Michael, Buvaylo, Viktoriya, Fletcher, Monique, Childs, Barrett H., Zinzani, Pier Luigi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9407680/
https://www.ncbi.nlm.nih.gov/pubmed/34389273
http://dx.doi.org/10.1016/j.clml.2021.06.021

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9407680/
https://www.ncbi.nlm.nih.gov/pubmed/34389273
http://dx.doi.org/10.1016/j.clml.2021.06.021

Ejemplares similares